KA
AVNS icon

Keene & Associates’s Avanos Medical AVNS Stock Holding History

Keene & Associates’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,165
Closed -$437K – 77
2024
Q3 		$437K Sell
18,165
-470
-3% -$10.7K 0.33% 55
2024
Q2 		$371K Buy
18,635
+2,585
+16% +$50.3K 0.3% 54
2024
Q1 		$320K Buy
16,050
+5,875
+58% +$114K 0.24% 68
2023
Q4 		$228K Sell
10,175
-3,500
-26% -$72.3K 0.19% 75
2023
Q3 		$277K Buy
13,675
+1,533
+13% +$34.8K 0.22% 68
2023
Q2 		$310K Buy
12,142
+475
+4% +$12.5K 0.24% 63
2023
Q1 		$347K Buy
+11,667
New +$339K 0.27% 56
2022
Q4 		– Sell
-11,917
Closed -$260K – 77
2022
Q3 		$260K Buy
11,917
+275
+2% +$7.18K 0.24% 64
2022
Q2 		$318K Buy
11,642
+1,132
+11% +$32.5K 0.3% 55
2022
Q1 		$352K Buy
10,510
+2,745
+35% +$88.4K 0.29% 57
2021
Q4 		$269K Buy
+7,765
New +$251K 0.23% 68

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Keene & Associates's AVNS Position: Q4 2024 in Review

Keene & Associates sold out of Avanos Medical (AVNS) in Q4 2024, closing a stake of 18,165 shares — an estimated $437K sold.

Keene & Associates first reported a position in AVNS in Q4 2021 and held it in 11 quarters. The position peaked at $437K in Q3 2024. 258 funds tracked by Wall St. Rank hold AVNS as of Q4 2024.

  • Keene & Associates reported no remaining Avanos Medical position as of Q4 2024 after selling out during the quarter.
  • Keene & Associates sold 18,165 Avanos Medical shares in Q4 2024, an estimated $437K.
  • Keene & Associates first reported a position in Avanos Medical in Q4 2021 and held it in 11 quarters.
  • Keene & Associates's Avanos Medical position peaked at $437K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.